Streetbeat News

Equity Actions

AHT

Ashford Hospitality Trust has entered into an agreement to sell the Hilton Boston Back Bay for $171 million. This move is part of their strategic financial management and asset optimization efforts.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 1:17 pm

CRAI

CRA International's Board of Directors has approved a $35.0 million expansion of its existing share repurchase program, signaling confidence in the company's financial health and future prospects.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 1:11 pm

SPEC

Spectaire Holdings Inc. has announced plans to expand its manufacturing capabilities, targeting the production of 500 AireCore units on a monthly basis. This strategic move is aimed at meeting growing demand and enhancing the company's market position.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 1:08 pm

TGNA

TEGNA announced its plan to return 40-60% of its 2024-2025 free cash flow to shareholders, amounting to an expected $1.3 billion return of capital from the date of merger termination through 2025, including a $350 million commitment in 2024.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 1:07 pm

ACHV

Achieve Life Sciences announced a registered direct offering of 13,086,151 shares at $4.585 per share, raising $124.2 million. Concurrently, a private placement will issue unregistered warrants to purchase an equal number of shares at $4.906 each.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 1:05 pm

ZUO

In the past three months, Zuora (NYSE:ZUO) received mixed analyst ratings, with a shift towards a neutral stance in the last 30 days. The average 12-month price target for ZUO has increased to $12.4, up from $10.00, indicating a positive outlook from analysts. Zuora's financials show a revenue growth of 8.68% but lag behind industry peers, with challenges in profitability, asset utilization, and a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 1:01 pm

RXST

Analysts have recently updated their ratings and price targets for RxSight (NASDAQ:RXST), showing a mix of bullish and somewhat bullish opinions. The average 12-month price target has been raised to $47.44, indicating a positive outlook. Key financial indicators reveal RxSight's strong revenue growth but challenges in profitability and asset utilization. The company, focusing on intraocular lens technology post-cataract surgery, shows a positive revenue trend but struggles with net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 1:00 pm

MSFT

NVDA

Figure AI announced it has raised $675 million at a valuation of $2.6 billion and signed a collaboration agreement with OpenAI. The funding round includes investments from Microsoft, OpenAI Startup Fund, Nvidia, and Jeff Bezos.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 12:59 pm

APP

AppLovin announced the pricing of a secondary offering of 19,866,397 shares of its Class A common stock by KKR Denali Holdings L.P., clarifying that it will not receive any proceeds from the sale.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 12:50 pm

PNW

Pinnacle West Capital has announced the pricing of its registered public offering of 9,774,436 shares of its common stock, aiming to raise approximately $630.5 million in net proceeds.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 12:32 pm